VRNA
Verona Pharma plc
$106.25
+$0.23(+0.22%)
83
Overall
--
Value
83
Tech
--
Quality
Market Cap
$9.16B
Volume
1.24M
52W Range
$27.54 - $106.45
Target Price
$106.22
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | -- | -- | $-33.0K | -- | $40.0M | $458.0K | -- | $42.3M | ||
| Total Revenue | -- | -- | $-33.0K | -- | $40.0M | $458.0K | -- | $42.3M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | $474.0K | -- | -- | $346.0K | -- | $2.6M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | -- | -- | $-507.0K | -- | $40.0M | $112.0K | -- | $39.7M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $26.2M | $25.6M | $52.4M | $74.3M | $113.3M | $66.2M | $67.6M | $196.9M | ||
| Research & Development | $23.7M | $19.3M | $42.4M | $44.5M | $79.4M | $49.3M | $17.2M | $44.6M | ||
| Research Expense | $23.7M | $19.3M | $42.4M | $44.5M | $79.4M | $49.3M | $17.2M | $44.6M | ||
| Selling, General & Administrative | -- | $6.3M | $10.0M | $29.8M | $33.9M | $26.6M | $50.4M | $149.8M | ||
| General & Administrative Expenses | -- | $6.3M | $10.0M | $29.8M | $33.9M | $26.6M | $50.4M | $149.8M | ||
| Salaries & Wages | -- | $-2.9M | $-3.1M | -- | -- | $14.1M | $19.0M | $41.2M | ||
| Depreciation & Amortization | -- | -- | $-382.0K | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | $-382.0K | -- | -- | -- | -- | -- | ||
| Securities Amortization | $2.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $692.0K | $651.0K | $600.0K | $700.0K | $2.6M | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-26.2M | $-25.6M | $-52.4M | $-74.3M | $-73.3M | $-75.8M | $-67.6M | $-154.6M | ||
| EBITDA | $-25.1M | $-22.7M | $-40.0M | $-64.3M | $-54.6M | $-67.1M | $-53.0M | $-160.6M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $35.0K | $340.0K | $521.0K | $2.1M | -- | ||
| Intinc | $7.0M | $2.8M | $11.3M | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $7.0M | $2.8M | $12.3M | $-35.0K | $-340.0K | $-2.3M | $-10.7M | -- | ||
| Gain on Sale of Securities | $-29.0K | -- | -- | $121.0K | $14.0K | $2.8M | $12.8M | $15.3M | ||
| Other Income/Expense | $29.0K | $-38.0K | $2.1M | $-7.3M | $-17.9M | $-4.6M | $-12.8M | $-11.6M | ||
| Other Special Charges | -- | $4.2M | $-2.1M | $7.1M | $17.9M | $-815.0K | -- | $-3.7M | ||
| SPECIAL ITEMS | ||||||||||
| Special Income Charges | $-29.0K | $38.0K | -- | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | $1.3M | -- | $289.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-25.2M | $-22.8M | $-40.5M | $-65.0M | $-55.2M | $-67.9M | $-53.9M | $-163.1M | ||
| Pre-Tax Income | $-25.2M | $-22.8M | $-40.5M | $-65.0M | $-55.6M | $-68.4M | $-53.9M | $-163.1M | ||
| INCOME TAX | ||||||||||
| Tax Provision | $-4.7M | $-4.2M | $72.0K | $146.0K | $-18.0K | $253.0K | $474.0K | $10.3M | ||
| NET INCOME | ||||||||||
| Net Income | $-20.5M | $-19.9M | $-40.6M | $-65.1M | $-55.6M | $-68.7M | $-54.4M | $-173.4M | ||
| Net Income (Continuing Operations) | $-20.5M | $-19.9M | $-40.6M | $-65.1M | $-55.6M | $-68.7M | $-54.4M | $-173.4M | ||
| Net Income (Discontinued Operations) | $-20.5M | $-19.9M | $-40.6M | $-65.1M | $-55.6M | $-68.7M | $-54.4M | $-173.4M | ||
| Net Income (Common Stockholders) | $-20.5M | $-19.9M | $-40.6M | $-65.1M | $-55.6M | $-68.7M | $-54.4M | $-173.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-161.5M | ||
| TOTALS | ||||||||||
| Total Expenses | $26.2M | $25.6M | $52.4M | $74.3M | $113.3M | $66.6M | $67.6M | $196.9M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $89.2M | $105.1M | $105.3M | $262.9M | $473.2M | $529.1M | $634.1M | -- | ||
| Average Shares Outstanding (Diluted) | $89.2M | $105.1M | $105.3M | $262.9M | -- | $529.1M | $634.1M | -- | ||
| Shares Outstanding | $105.0M | $105.3M | $105.3M | $463.5M | $86.2M | $631.9M | $646.5M | $679.8M | ||
| Basic EPS | $-0.23 | $-18.9 | $-30.3 | $-0.25 | $-0.12 | $-0.13 | $-0.69 | -- | ||
| Basic EPS (Continuing Operations) | $-0.23 | $-18.9 | $-30.3 | $-0.25 | $-0.12 | $-0.13 | $-0.09 | -- | ||
| Diluted EPS | $-0.23 | $-18.9 | -- | $-0.25 | $-0.12 | $-0.13 | $-0.69 | -- | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.13 | $-0.09 | -- | ||
| OTHER METRICS | ||||||||||
| Acquired In Process Rn D | $-29.0K | $38.0K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | -- | $6.3M | $10.0M | $29.8M | $33.9M | $26.6M | $50.4M | $149.8M | ||
| Other Write Off | $2.5M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRNA | $106.25 | +0.2% | 1.24M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |